Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.78 USD | +5.41% | +8.33% | -5.07% |
Mar. 18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Camac Partners Provides Information to Shareholders | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 28.39M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.1% |
1 day | +5.41% | ||
1 week | +8.33% | ||
Current month | +12.04% | ||
1 month | +21.27% | ||
3 months | +12.13% | ||
6 months | +35.32% | ||
Current year | -5.07% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Wagner
CEO | Chief Executive Officer | 53 | 16-12-31 |
Anthony Riley
DFI | Director of Finance/CFO | 57 | 20-02-29 |
Chief Operating Officer | - | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Gryska
BRD | Director/Board Member | 68 | 23-01-09 |
Steven Kornfeld
BRD | Director/Board Member | 56 | 20-05-31 |
Director/Board Member | 65 | 22-05-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.78 | +5.41% | 57,459 |
24-04-17 | 0.74 | +0.87% | 57,261 |
24-04-16 | 0.7336 | +3.32% | 17,825 |
24-04-15 | 0.71 | -1.84% | 6,388 |
24-04-12 | 0.7233 | +0.46% | 22,179 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.07% | 28.39M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.43% | 21.66B | |
-18.35% | 20.77B | |
-8.72% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- FBRX Stock